Dew, I thought you said that it is typical for a company to not release interim data for Phase 3? Why, then, could ADXS be faulted if it does the same?
This has been my biggest fear with ADXS, but I'd expect to see more insider selling if this was the case. Its hard to argue DOC didn't believe in the science.
A cynic might say that delaying the results... enables management to string investors along for several years ...
from: Mechanistic insights into ADXS11-001 human papillomavirus-associated cancer immunotherapy (2017)
Brett A. Miles1*, Bradley J. Monk2 and Howard P. Safran3
CONCLUSIONS: ... The current clinical status of AXAL, which continues to be assessed in patients with HPV-associated cancers at different stages, provides optimism for the future of the vaccine in the treatment of these malignancies. Administered alone or in combination with various cancer therapies, AXAL has been proven to be well tolerated by patients with HPV-associated cancers in multiple investigations, with early promising signs of antitumor activity also being reported. These encouraging findings pave the way for AXAL phase III clinical trials and, at later stages, the potential introduction of AXAL into the clinical setting. /CONCLUSIONS
This is the sort of stuff that keeps my cynicism at bay! How long can you string Drs. Miles,Monk and Safran along?
So now you think GOG Institute run trials is bogus? Funny cause they ran Avastatin trials too? The FDA recommended the Phase3 trial were running now? They are the reason we're not running a phase 3 HPV metastatic cervical cancer trial ? The FDA! Evidently they feel our safety and efficacy for HPV metastatic cevical cancer is just fine ? I don't think Advaxis would have purposely shot themselves in the foot if they thought the FDA wanted more data on the HPV metastatic cervical cancer. Advaxis is working very closely with the FDA on all trials from here on in . Hopefully we get more data in the coming months!